Postcontrast liver attenuation measured with coronary CT angiography demonstrated promising diagnostic performance for opportunistic identification of moderate-to-severe hepatic steatosis using tube potential–specific thresholds and was associated with coronary artery Agatston score.

Colorectal cancer (CRC) ranks among the foremost causes of cancer-related mortality, with liver metastases (colorectal liver metastases, CLM) considerably affecting prognosis. While surgery is the gold standard for curative treatment, the majority of patients are ineligible due to disease extent or comorbidities. Radioembolization with yttrium-90 (Y-90) microspheres has emerged as a promising locoregional therapy for unresectable CLM. However, its effectiveness in improving survival and tumor control remains an area of active investigation. The clinical results of 59 colorectal cancer patients with liver metastases who received radioembolization treatment were assessed. Treatment response was assessed using imaging modalities, including PET-CT, MRI, and CT. The primary endpoints were overall survival (OS) and treatment response, while secondary outcomes included toxicity profiles and prognostic factors influencing survival. The cohort’s median OS was 9 months, with a mean OS of 13.2 months. Patients exhibiting metabolic response on PET-CT had significantly longer survival (19.3 months) compared to non-responders (8.3 months, p = 0.042). Extrahepatic disease was a strong prognostic factor, with patients without extrahepatic involvement showing a significantly lower OS (7.1 vs. 21 months, p = 0.000). Bilobar disease also negatively impacted survival (p = 0.003). Nearly all patients experienced mild to moderate side effects, with the most common being abdominal pain, nausea, and vomiting. Severe toxicities were rare, although one patient developed a gastric ulcer.Y-90 radioembolization is an effective and relatively safe treatment for unresectable CLM, particularly in patients without extrahepatic disease. The strong association between metabolic response and survival underscores the potential of PET-CT as a prognostic indicator. Further prospective studies are needed to refine patient selection criteria and optimize treatment protocols.

Breast cancer is the most common malignancy in women worldwide, and accurate assessment of tumor size plays a critical role in treatment planning and surgical decision-making. Breast magnetic resonance imaging (MRI) is a highly sensitive modality for lesion detection and evaluation of disease extent. Comprehensive image interpretation can be time-consuming, prompting interest in faster and more practical assessment techniques. The study aimed to evaluate the accuracy of tumor size estimation using only maximum intensity projection (MIP) images from dynamic contrast-enhanced breast MRI and to assess interobserver agreement. In this retrospective study, 65 female patients with histopathologically confirmed breast cancer who underwent preoperative breast MRI. Post-contrast three-dimensional MIP images were independently and blindly evaluated by two observers with different experience levels: a breast radiology resident and an experienced breast radiologist. The longest diameter of the index lesion was measured on MIP images. Histopathological tumor size was accepted as the reference standard. Interobserver agreement and agreement with pathology were assessed using intraclass correlation coefficients (ICC). Subgroup analyses were performed based on lesion type, molecular subtype, and presence of in-situ components. Breast MRI MIP images-based tumor size measurements demonstrated strong correlation with histopathological findings. (Observer 1: ICC=0.835; Observer 2: ICC=0.890; p<0.001). The interobserver agreement among radiologists was found to be good to excellent, regardless of experience level. (ICC=0.974; 95% CI: 0.945–0.987; p<0.001). In all subgroups, measurements from MIP images showed excellent correlation with pathology sizes. Agreement was higher for mass enhancement lesions than non-mass enhancement lesions. Correlation was slightly lower in the presence of in situ components, but overall agreement remained good. Tumor size measurements using only MIP images in staging breast MRI show high concordance with pathology sizes. MIP images can be used as a practical and reliable tool for tumor size assessment in early stage breast cancer, with high interobserver agreement.